AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
AIM ImmunoTech reported Q4 earnings with a loss of $(0.26) per share, missing the $(0.15) estimate by 73.33%, and a 188.89% decrease from last year. Sales were $65K, beating the $40K estimate by 62.5% and marking a 16.07% increase from last year.
April 03, 2024 | 2:58 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AIM ImmunoTech reported a larger than expected quarterly loss but exceeded sales estimates in Q4.
The mixed results with a significant miss on EPS but a beat on sales revenue could lead to neutral market reaction. Investors might be concerned about the increased losses but could also be optimistic about the higher sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100